

Requesting Nominations for Consumer Representative for the Advisory Committee on Reproductive Health Drugs

The Center for Drug Evaluation and Research is actively recruiting nominees for the position of Consumer Representative on several of its Advisory Committees, including the Advisory Committee for Reproductive Health Drugs (ACRHD), which has a current vacancy. (Mr. Merrill Goozner, the Consumer Representative appointed to the Advisory Committee for Pharmaceutical Science and Clinical Pharmacology has kindly agreed to serve as Acting Consumer Representative for the September 8 meeting.)

The next few pages include information on the Consumer Representative position, and contact information for all of CDER's Advisory Committees.

Some additional information:

- Consumer Representatives are appointed for terms of up to 4 years, and are invited to participate in all of the Committee's meetings during their term. (The ACRHD typically meets 1-2 times per year.)
- All Advisory Committee Members, including the Consumer Representative, are screened for conflict of interest before every meeting or project. Nominees with minimal ties to the pharmaceutical industry are preferred.
- Most meetings take place in the Washington DC area. Advisory Committee Members attending the meeting receive salary and travel arrangements and expenses as allowed under government regulations.
- There is no specific educational requirement for the Consumer Representative.

Further information on FDA Advisory Committees can be found at <http://www.fda.gov/oc/advisory/default.htm>

If you are interested in nominating yourself, or someone else, for the Consumer Rep position on the ACRHD, please send a current CV, which includes information on your ties to consumer organizations, to Kalyani Bhatt at Kalyani.Bhatt@fda.hhs.gov.

Thank you for your time and consideration.

FDA Advisory Committees

Consumer Representative

A consumer representative has an important role in FDA advisory committee deliberations. To qualify, he or she must be able to analyze scientific data, understand research design, discuss benefits and risks, and evaluate the safety and efficacy of products under review. It is also required that the representative have an affiliation with and/or active participation in consumer or community-based organizations. FDA takes a variety of actions to help find as broad a selection of candidates as possible, including qualified experts with the least potential conflicts of interest. Further information on FDA Advisory Committees can be found at <http://www.fda.gov/oc/advisory/default.htm>

Roles and Responsibilities

- ◀ Represent the consumer perspective on issues and actions before the advisory committee.
- ◀ Serve as a liaison between the committee and interested consumers, associations, coalitions, and consumer organizations.
- ◀ Facilitate dialogue with the advisory committees on scientific issues that affect consumers.

If you would like to nominate a colleague or yourself, please forward the following information to the address listed below.

- ◀ a cover letter,
- ◀ a *curriculum vitae* or resumé (including the nominee's home and business address, telephone number, and e-mail), and
- ◀ a name of the consumer or community-based organization(s) for which you can demonstrate active participation.



Protecting the Public Health. You can be part of the process.

CENTER FOR DRUG EVALUATION AND RESEARCH
ADVISORY COMMITTEE CONTACT INFORMATION

| Advisory Committee | Designated Federal Officer | E-mail / Phone number |
|--|-----------------------------------|--|
| Anesthetic and Life Support Drugs (ALSDAC) | Kalyani Bhatt | Kalyani.Bhatt@fda.hhs.gov (301) 827-7001 |
| Anti-Infective Drugs (AIDAC) | Janie Kim | Janie.Kim@fda.hhs.gov (301) 827-7001 |
| Antiviral Drugs (AVAC) | Paul Tran | Paul.Tran@fda.hhs.gov (301)-827-7001 |
| Arthritis (AAC) | Nicole Vesely | Nicole.Vesely@fda.hhs.gov (301) 827-6793 |
| Cardiovascular & Renal Drugs (CRDAC) | Elaine Ferguson | Elaine.Ferguson@fda.hhs.gov (301) 827-6768 |
| Dermatologic & Ophthalmic Drugs (DODAC) | Yvette Waples | Yvette.Waples@fda.hhs.gov (301) 827-7001 |
| Drug Safety & Risk Management (DSaRM) | Elaine Ferguson | Elaine.Ferguson@fda.hhs.gov (301) 827-6768 |
| Endocrinologic & Metabolic Drugs (EMDAC) | Paul Tran | Paul.Tran@fda.hhs.gov (301)-827-7001 |
| Gastrointestinal Drugs (GIDAC) | Kristine Khuc | Kristine.Khuc@fda.hhs.gov (301) 827-7001 |
| Nonprescription Drugs (NDAC) | Diem-Kieu Ngo | Diem.Ngo@fda.hhs.gov (301) 827-6765 |
| Oncologic Drugs (ODAC) | Nicole Vesely | Nicole.Vesely@fda.hhs.gov (301) 827-6793 |
| Peripheral & Central Nervous System Drugs (PCNS) | Diem-Kieu Ngo | Diem.Ngo@fda.hhs.gov (301) 827-6765 |
| Pharmaceutical Science & Clinical Pharmacology (ACPS-CP) | Sohail Mosaddegh | Sohail.Mosaddegh@fda.hhs.gov (301) 827-7001 |
| Psychopharmacologic Drugs (PDAC) | Yvette Waples | Yvette.Waples@fda.hhs.gov (301) 827-7001 |
| Pulmonary-Allergy Drugs (PADAC) | Kristine Khuc | Kristine.Khuc@fda.hhs.gov (301) 827-7001 |
| Reproductive Health Drugs (ACRHD) | Kalyani Bhatt | Kalyani.Bhatt@fda.hhs.gov (301) 827-7001 |